Scopus Biopharma, Inc. (SCPS)
| Market Cap | 67.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.25M |
| Shares Out | 16.19M |
| EPS (ttm) | -1.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,916 |
| Open | 3.75 |
| Previous Close | 3.77 |
| Day's Range | 3.67 - 3.75 |
| 52-Week Range | 3.66 - 47.86 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About SCPS
Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis. Scopus BioPharma Inc. has strategic partnerships wi...
Financial Performance
Financial StatementsNews
Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signific...
Scopus BioPharma to Present at the LD Micro Main Event
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology
Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct...
Scopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas Conference
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Ann...
Data from two different studies benchmark Duet's proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice
Scopus BioPharma's Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the ...
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its pr...
Scopus BioPharma's Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of ...
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its pr...
Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signifi...
Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Ther...
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors
China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 In...
New patent covers compound and composition and methods of use for CpG-STAT3 Antisense inhibitor (CpG-STAT3ASO)
Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Bo...
JERUSALEM, Sept. 20, 2021 /PRNewswire/ -- Dr. Morris C.
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scie...
Dr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope Natio...
Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on Clinical Development of CpG-STAT3 Inhibitors Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Pr...
What Is Happening With Scopus BioPharma Stock On Thursday?
Scopus BioPharma Inc (NASDAQ: SCPS) has launched Duet Therapeutics that integrates the management and clinical development of the immunotherapy assets of Scopus and Olimmune. Related Content: Scopus Bio...
Scopus BioPharma Launches Duet Therapeutics
Duet Therapeutics Integrates Immunotherapy Assets of Scopus and Olimmune, Acquired by Scopus in June 2021
5 Best Penny Stocks To Buy Right Now According To Insiders
5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Scopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy Company
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signific...
Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune
Transaction Creates Global Leader in Oligonucleotide Cancer Therapeutics
Scopus BioPharma Announces New Date for 2021 Annual Meeting of Stockholders
NEW YORK, May 31, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced that the board of directors has rescheduled the company's 2021 Annual Meeting of Stockholders (“2021 Ann...
Scopus BioPharma to Reschedule 2021 Annual Meeting of Shareholders
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced it will be rescheduling the company's 2021 Annual Meeting of Shareholders (the “2021 Annual Meeting”), w...
Why Scopus BioPharma's Stock Is Surging Today
Scopus BioPharma (NASDAQ:SCPS) shares are trading higher after the company announced the FDA has approved its IND application for CpG-STAT3siRNA, the company's distinctive immuno-oncology RNA therapy fo...
SCPS Stock: The Huge FDA News Sending Scopus BioPharma Up 100%
Today, investors in SCPS stock are seeing their investment more than double on a key announcement of an FDA approval for a core therapy. The post SCPS Stock: The Huge FDA News Sending Scopus BioPharma U...
Why Scopus, NGM Biopharma and Taiwan Liposome Are Moving Today
Scopus BioPharma Inc. (NASDAQ: SCPS), NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) and Taiwan Liposome Company, Ltd. (NASDAQ: TLC) are among the biggest biopharma movers Monday.
Why Scopus BioPharma Stock More Than Double Today?
The FDA has signed off investigational new drug application of Scopus BioPharma Inc's (NASDAQ: SCPS) for CpG-STAT3siRNA, the company's distinctive immuno-oncology RNA therapy for the treatment of multip...
Why Did Scopus BioPharma's Stock More Than Double Today?
The FDA has signed off investigational new drug application of Scopus BioPharma Inc's (NASDAQ: SCPS) for CpG-STAT3siRNA, the company's distinctive immuno-oncology RNA therapy for the treatment of multip...